BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...entospletinib in acute myelogenous leukemia patients with NPM1...
...CD40 ligandCRF1 – Corticotropin-releasing factor 1NPM1 (B23...
BioCentury | Jul 17, 2020
Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

...Phase I/II trial and found another biomarker seemed to be indicative of entospletinib activity: mutant NPM1...
...with high HOXA9/MEIS1 expression, meaning a companion diagnostic was no longer necessary. A test for NPM1...
...Meis homeobox 1 MYC (c-Myc) - v-myc myelocytomatosis viral oncogene homolog NPM1 (B23) - Nucleophosmin...
BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

...China for its use against coronavirus (see “O’Day on Remdesivir” ). Syndax’s SNDX-5613 to prevent NPM1-mutant...
...after disease onset and increased survival when delivered before tumor onset in mouse models of NPM1-mutant...
...neoplasia I MLL1 (MLL; HRX; KMT2A) - Myeloid-lymphoid or mixed-lineage leukemia protein NPM1 (B23) - Nucleophosmin BioCentury...
BioCentury | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

...AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of nucleophosmin (NPM1; B23...
...and sensitivity to Imbruvica ibrutinib in tumors harboring FLT3 mutations alone or in combination with NPM1...
...PLX4032 (Compound #), vemurafenib (Generic) Oregon Health & Science University CD86 (B7-2) FMS-like tyrosine kinase 3 (FLT3) (CD135) MicroRNA-223 (miR-223) Nucleophosmin (NPM1) (B23) Acute...
BioCentury | Aug 22, 2016
Company News

Rasna, Active With Me deal

...The combined company retained Rasna’s name and will focus on modulating nucleophosmin ( NPM1 ; B23...
BioCentury | May 19, 2014
Finance

Highlights of weekly biotech stock moves

...in metastatic melanoma. The product is a sterile injection containing 10% rose bengal disodium (see B23...
BioCentury | May 5, 2014
Finance

Highlights of weekly biotech stock moves

...exploratory and therefore not powered to reach a p-value of <0.05 on the endpoint (see B23...
BioCentury | Apr 7, 2014
Finance

Highlights of weekly biotech stock moves

...primary endpoint vs. placebo in a Japanese Phase II trial to treat primary hypercholesterolemia (see B23...
BioCentury | Mar 10, 2014
Analyst Picks & Changes

Analyst picks & changes

...non-infectious uveitis and Behcet's uveitis and in Phase II testing to treat pyoderma gangrenosum (see B23...
BioCentury | Nov 25, 2013
Analyst Picks & Changes

Analyst picks & changes

...trial program in the indication. Reolysin is a formulation of human reovirus type 3 (see B23...
Items per page:
1 - 10 of 130